DOCSLIB.ORG

The Effect of Barbiturates in Patients with Liver Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of Barbiturates in Patients with Liver Disease THE EFFECT OF BARBITURATES IN PATIENTS WITH LIVER DISEASE John T. Sessions Jr., … , John C. Bullard, Franz J. Ingelfinger J Clin Invest. 1954;33(8):1116-1127. https://doi.org/10.1172/JCI102985. Research Article Find the latest version: https://jci.me/102985/pdf THE EFFECT OF BARBITURATES IN PATIENTS WITH LIVER DISEASE' BY JOHN T. SESSIONS, JR.,2 HERBERT P. MINKEL, JOHN C. BULLARD, AND FRANZ J. INGELFINGER (From the Evans Memorial, Massachusetts Memorial Hospitals, the Boston Veterans Adminis- tration Hospital and the Department of Medicine, Boston University School of Medicine, Boston, Mass.) (Submitted for publication May 27, 1952; accepted March 22, 1954) Although sedatives are frequently required in 1. Do barbiturates damage the liver itself? the treatment of patients with liver disease, bar- 2. Are patients with liver disease more sensitive biturates are believed to be contraindicated in the to barbiturates because of impaired inactiva- face of impaired hepatic function. Three points tion of these drugs by the damaged liver? are advanced in support of this belief: First, pa- 3. Are patients with liver disease more sensi- tients with advanced liver disease have remained tive to barbiturates because of increased sen- comatose for long periods of time after receiving sitivity of the nervous system? a barbiturate; second, animals after chloroform in- Information bearing on these questions was duced hepatic damage or partial liver extirpation sought by comparing the effect of barbiturates in have shown an increased sensitivity to anesthetic control subjects and patients with liver disease. doses of barbiturates (1, 2); and third, animals Pentobarbital (Nembutal@) was the barbiturate are alleged to show a greater than normal retention principally used because it is a popular drug; and of pentobarbital and barbital in their blood and is said to be inactivated by the liver. The effects tissues after chloroform anesthesia (3). These of both single doses and prolonged administration points of evidence, however, are far 'from con- of barbiturate were observed. clusive. The natural progression of hepatic coma from a stage of restlessness to one of somnolence, EFFECTS OF SINGLE DOSES OF BARBITURATE and the spontateous fluctuations that occur in the Material and methods. course of liver disease reduce the significance of Pentobarbital was gieven to 35 control subjects without temporal correlations in determining the part any liver or central nervous system disease and to 21 patients single factor plays in causing hepatic coma. As with liver disease. As indicated in Table I, all of these far as animal experiments are concerned, they are patients except one had signs and symptoms of advanced hepatic damage. Seventeen of these patients had cir- not necessarily applicable to man, particularly if rhosis with an alcoholic background but at the time of the type of liver damage and the barbiturate dosage the acute studies were suffering neither from alcoholism are not comparable to the usual clinical situation. nor its withdrawal symptoms. After preliminary stud- Finally, methods of barbiturate analysis are diffi- ies showed that oral doses were well tolerated, intra- venous administration (sodium pentobarbital) was used cult and non-specific. Since the evidence incrimi- routinely in subsequent studies to eliminate the variables nating the use of barbiturates in liver disease of intestinal absorption and to provide a sharp beginning seemed circumstantial, a study to obtain direct evi- point for both clinical and biochemical measurements. dence was undertaken. Three in The drug was given either as a single injection during the questions par- course of one-half minute or as a constant intravenous ticular seemed worthy of consideration: infusion over a 30-minute period. Single injections were given 40 times to patients with liver disease and 35 times 1 The work reported herein was supported by a contract to control subjects. The doses varied from 30 to 240 mg., from the Veterans Administration upon recommendation but in 75 per cent of the tests 100 to 120 mg. was used. of the National Research Council's Committee on Veterans Doses given to control and patient groups were com- Medical Problems. parable. Intravenous infusions containing 100 to 180 mg. 2 Present address: Department of Medicine, University of sodium pentobarbital in 120 ml. were given to 10 pa- of North Carolina, Chapel Hill, N. C. tients with liver disease and to seven control subjects. 1116 EFFECT OF BARBITURATES IN PATIENTS WITH LIVER DISEASE 1117, TABLE I barbiturate effects. The learning factor, varying IXAGNOSES AND EVOENCES OF HEPATIC D N THE PATEN STLUIED effects of pentobarbital on mood, the degree of AM.mmSoteimmisdI I.525.5 dnam27 I patient cooperation and differences in educational PATIENTS GNVEN SINGLE DOSE OF BARIBITURATE-ACUTE STUDIES background made the interpretation of reading and I|C.R. | L=' | NO | YES 2:1 GA^ 26 ndono 21 H-K- 2.7 |18.8 75 11 mathematical tests difficult. No definite changes 3 M.C .1 2.1 5.7 348 in temperature, pulse, respiration and blood pres- 4 S.V. a 2.3 2.3 50 __ _ JO.. YESO Y 2.5 .6 45 II sure were noted in either patients or control sub- 6 E.D. 2o. 2.05 30 s jects after barbiturates were given. 7 J.C. NO I' 2.6 11.0 26 E 1.1 n1.I25.5 2 Intravenous administration of 60 mg. or less of 9 H. " YES .93.I 4 30 4. sodium pentobarbital produced minimal changes, 10 F Rt,l l 2.1 7.8 27_ of 9 L.f 2.o 0.5 30 4f nystagmus on lateral gaze and slight variations in 12 J. F. u 2.2 431 48 I 13 m^.c. 2.0 2.7 4 mood (euphoria, sense of "relaxation") being the 14 C .S. ,l NO 1lI.7 2.1 65 usual effects of the drug. Barbiturate activity be- _5 J .H. not movi 2.0 2.8 75 Is W.W. II NO 2.3 7.0 37 gan within one-half minutes of injection and per- 17 O .H. NO YES 2.8 I .8 TO sisted for 15 to 30 minutes. Is G. Hepotanm YES 2l25 2.8 69 Larger intravenous doses of pentobarbital (100 19. W.Q l NO l 2 .5 I .7 65 of 0O .T. Cirs YES 1" 2 .0 7 .4 48 u to 180 mg.) intensified the nystagmus and changes 21.LHoett No NO 4.4 O.8 70 H in mood and induced other measurable effects. FATIWS GIVE REPEAE DOSES OF IATfURATE - PRLNE STUDIES Nystagmus, as it increased, occurred in the vertical |C |Carks NO YES not done 3.3 |35 4+ -21-Q I T @ I I T 10.8 28 4+ as well as horizontal plane and was accompanied 3r T | 1 YES § |5 6 |42 | 4+ frequently by blurred vision and occasionally by -4 ktnot ewmarind 1 _ T4.3 68 4v 5 C- YES 1lI.5 42 4 diplopia. Slurred speech or abnormally precise 6 D , NO l 2.0 45 4* speech usually began in the first five minutes of 7 tC. NO l l12239 4 8 H YES .- 3.0 4.0 30 4 the post-medication period and subsided during C--,noof exrined l a oe . 6 4 I-lto l l l 4 . 1 4 the following 20 minutes. Impaired two-point discrimination was found to correlate well with Evaluation of barbiturate effects was attempted by the over-all pentobarbital effect. Usually the three general methods: clinical observation, liver function threshold for two-point discrimination increased tests and measurement of pentobarbital blood levels. by 50 to 100 per cent after injecting the drug; this Since there are no established methods for measuring increase was maximal during the first 15 minutes either clinical manifestations or pentobarbital blood levels that follow the intravenous injection of ordinary hyp- and seldom persisted for more than 30 minutes. notic doses of pentobarbital, the choice, development and The larger doses of pentobarbital also increased adequacy of methods used by us are discussed in some the degree of euphoria. The subjects were fre- detail. quently more garrulous and likened the effect to Clinical observations. that produced by alcohol. Within 15 minutes, When it appeared that the doses used in our TABLE II study would not elicit the signs described as char- Clinical observations made on the effects of single doses of barbiturate acteristic of acute and chronic barbiturate intoxica- tion, a number of other neuropsychologic tests Times performed were investigated. The tests listed in Table II Patients with liver Control were performed before the barbiturate was given Tests disease subjects and at 5 to 30 minute intervals thereafter for one Nystagmus 20 28 or until all evidences of had Slurred speech 15 28 hour, drug effect Two-point discrimination 15 28 disappeared. The most useful tests for following Changes in mood and level of the effects of consciousness 40 35 pentobarbital proved to be nystagmus, Deep-tendon reflexes 22 18 slurred speech, two-point discrimination and evalu- Finger to nose 29 16 Mathematical problems 18 7 ation of changes in mood and levels of conscious- Reading test 9 6 ness. Other tests were omitted when it became Corneafreflex 9 6 apparent that they were of little help in assessing Temperature, pulse, respirations 9 6 1118 3. T. SESSIONS, JR., H. P. MINXEL, J. C. BULLARD, AND F. J. INGELFINGER TABLE iIia The effect of pentobarbital, 100-120 mg. I. V. as a single injection, on 28 control subjects Degree of drug effect-0 to 4 Sum Duration of drug effect in minutes of Pt. Age Diagnosis Test 0 15 30 4S 60 75 90 effect Given in 2 ml.
Load more

Recommended publications
  • Kava (Piper Methysticum) and Its Methysticin Constituents Protect Brain Tissue Against Ischemic Damage in Rodents
    5 Refs: Arletti R et al, Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual-behavior of male rats. Psychopharmacology 143(1), 15-19, 1999. Berger F, Handbuch der drogenkunde . Vol 2, Maudrich, Wien, 1950. Martinez M, Les plantas medicinales de Mexico . Cuarta Edicion Botas Mexico , p119, 1959. Tyler VE et al, Pharmacognosy , 9 th edition, Lea & Febiger, Philadelphia, 1988. KAVA ( Piper methysticum ) - A REVIEW The Kava plant (Piper methysticum) is a robust, well-branching and erect perennial shrub belonging to the pepper family (Piperaceae). The botanical origin remains unknown, although it is likely that early Polynesian explorers brought the plant with them from island to island. Numerous varieties of Kava exist, and today it is widely cultivated in several Pacific Island countries both for local use as well as the rapidly growing demand for pharmaceutical preparations. The dried rhizomes (roots) are normally used. The first description to the western world of the ceremonial use of an intoxicating beverage prepared from Kava was made by Captain James Cook following his Pacific voyage in 1768. The drink, prepared as an infusion in an elaborate manner after first chewing the root, is consumed on formal occasions or meetings of village elders and chiefs, as well as in reconciling with enemies and on a more social basis. It remains an important social custom in many Pacific Island countries today. Most of the islands of the Pacific possessed Kava prior to European contact, particularly those encompassed by Polynesia, Melanesia and Micronesia. After drinking the Kava beverage a pleasantly relaxed and sociable state develops, after which a deep and restful sleep occurs.
    [Show full text]
  • Alternative Treatments for Depression and Anxiety
    2019 PCB Conference: Strickland Benzodiazepines (BZDs), Herbal and Alternative Treatments for Anxiety & Depression BZD Learning Objectives • List at least three uses for benzodiazepines • Discuss at least two risk factors associated with benzodiazepine prescriptions Craig Strickland, PhD, Owner Biobehavioral Education and Consultation https://sites.google.com/site/bioedcon 1 2 BZD Pharmacokinetics Clinical Uses of BZDs Generic Name Trade Name Rapidity ½ Life Dose (mg) • Treat a variety of anxiety disorders alprazolam Xanax Intermediate Short 0.75-4 • Hypnotics • Muscle relaxants chlordiaze- Librium Intermediate Long 15-100 poxide • To produce anterograde amnesia clonazepam Klonopin Intermediate Long 0.5-4 • Alcohol & other CNS depressant withdrawal • Anti-convulsant therapy diazepam Valium Rapid Long 4-40 triazolam Halcion Intermediate Very short 0.125-0.5 temazepam Restoril Short Short 7.5-30 3 4 1 2019 PCB Conference: Strickland Issues with BZDs Herbal Medication and Alternative Therapies Used in the Treatment of Depression and Anxiety • Addictive potential • Confusion between “anti-anxiety” effects and the “warm-fuzzy) • Large dose ranges • Comparison of BZDs with medications like Buspar, etc. • They work, they work well and they work quickly 5 6 Alternative Tx. Learning Objectives Background Information on herbals: Natural does not necessarily mean “safe” • List several amino acid treatments for depression • Side-effects and adverse reactions • List at least three of the most common herbal – Herbal medications are “drugs” although
    [Show full text]
  • PENTOBARBITAL SODIUM- Pentobarbital Sodium Injection Akorn, Inc
    PENTOBARBITAL SODIUM- pentobarbital sodium injection Akorn, Inc. ---------- Nembutal® Sodium Solution CII (pentobarbital sodium injection, USP) + novaplus TM Rx only Vials DO NOT USE IF MATERIAL HAS PRECIPITATED DESCRIPTION The barbiturates are nonselective central nervous system depressants which are primarily used as sedative hypnotics and also anticonvulsants in subhypnotic doses. The barbiturates and their sodium salts are subject to control under the Federal Controlled Substances Act (See “Drug Abuse and Dependence” section). The sodium salts of amobarbital, pentobarbital, phenobarbital, and secobarbital are available as sterile parenteral solutions. Barbiturates are substituted pyrimidine derivatives in which the basic structure common to these drugs is barbituric acid, a substance which has no central nervous system (CNS) activity. CNS activity is obtained by substituting alkyl, alkenyl, or aryl groups on the pyrimidine ring. NEMBUTAL Sodium Solution (pentobarbital sodium injection) is a sterile solution for intravenous or intramuscular injection. Each mL contains pentobarbital sodium 50 mg, in a vehicle of propylene glycol, 40%, alcohol, 10% and water for injection, to volume. The pH is adjusted to approximately 9.5 with hydrochloric acid and/or sodium hydroxide. NEMBUTAL Sodium is a short-acting barbiturate, chemically designated as sodium 5-ethyl-5-(1- methylbutyl) barbiturate. The structural formula for pentobarbital sodium is: The sodium salt occurs as a white, slightly bitter powder which is freely soluble in water and alcohol but practically insoluble in benzene and ether. CLINICAL PHARMACOLOGY Barbiturates are capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia.
    [Show full text]
  • Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin Healthcare
    Benzodiazepines: Uses and Risks Charlie Reznikoff, MD Hennepin healthcare 4/22/2020 Overview benzodiazepines • Examples of benzos and benzo like drugs • Indications for benzos • Pharmacology of benzos • Side effects and contraindications • Benzo withdrawal • Benzo tapers 12/06/2018 Sedative/Hypnotics • Benzodiazepines • Alcohol • Z-drugs (Benzo-like sleeping aids) • Barbiturates • GHB • Propofol • Some inhalants • Gabapentin? Pregabalin? 12/06/2018 Examples of benzodiazepines • Midazolam (Versed) • Triazolam (Halcion) • Alprazolam (Xanax) • Lorazepam (Ativan) • Temazepam (Restoril) • Oxazepam (Serax) • Clonazepam (Klonopin) • Diazepam (Valium) • Chlordiazepoxide (Librium) 4/22/2020 Sedatives: gaba stimulating drugs have incomplete “cross tolerance” 12/06/2018 Effects from sedative (Benzo) use • Euphoria/bliss • Suppresses seizures • Amnesia • Muscle relaxation • Clumsiness, visio-spatial impairment • Sleep inducing • Respiratory suppression • Anxiolysis/disinhibition 12/06/2018 Tolerance to benzo effects? • Effects quickly diminish with repeated use (weeks) • Euphoria/bliss • Suppresses seizures • Effects incompletely diminish with repeated use • Amnesia • Muscle relaxation • Clumsiness, visio-spatial impairment • Seep inducing • Durable effects with repeated use • Respiratory suppression • Anxiolysis/disinhibition 12/06/2018 If you understand this pharmacology you can figure out the rest... • Potency • 1 mg diazepam <<< 1 mg alprazolam • Duration of action • Half life differences • Onset of action • Euphoria, clinical utility in acute
    [Show full text]
  • Is Alcohol Use Related to High Cholesterol in Premenopausal
    Research iMedPub Journals Journal of Preventive Medicine 2018 http://www.imedpub.com/ Vol.3 No.1:3 ISSN 2572-5483 DOI: 10.21767/2572-5483.100024 Is Alcohol Use Related To High Cholesterol in Premenopausal Women Aged 40-51 Years Old? Sydnee Homeyer, Jessica L Hartos*, Holli Lueg, Jessica Moore and Patricia Stafford Department of Physician Assistant Studies, University of North Texas Health Science Center, USA *Corresponding author: Jessica L. Hartos, Department of Physician Assistant Studies, University of North Texas Health Science Center, USA, Tel: 817-735-2454; Fax: 817-735-2529; E-mail: [email protected] Received date: November 13, 2017; Accepted date: January 8, 2018; Publication date: January 15, 2018 Citation: Homeyer S, Hartos JL, Lueg H, Moore J, Stafford P, et al. (2018) Is Alcohol Use Related To High Cholesterol In Premenopausal Women Aged 40-51 Years Old? J Prev Med Vol.3 No.3: 3. Copyright: © 2018 Homeyer S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. Introduction Abstract Increased serum cholesterol levels is a major risk factor for coronary heart disease (CHD) [1], and over seventy-one million Purpose: Alcohol use and cholesterol are related in men and American adults have high cholesterol (27%) [2,3]. In American postmenopausal women but relations between alcohol use women, cholesterol levels have been shown to increase with and cholesterol are unclear for premenopausal women. The age, and nearly 1 in 2 American women has high or borderline purpose of this study was to determine whether alcohol use was related to cholesterol in women aged 40-51 years old.
    [Show full text]
  • E the Effect of Topiramate on Weight Loss in Patients with Type 2 Diabetes
    E The effect of topiramate on weight loss in patients with type 2 diabetes RTICL Sedighe Moradi, Scott Reza Jafarian Kerman, Mina Mollabashi A Institute of Endocrinology and Metabolism (Hemmat Campus), Firoozgar Hospital, Tehran University of Medical Sciences, Tehran, Iran Background: Obesity has been associated with several co‑morbidities such as diabetes and increased mortality. In general, the use of medication promotes only a modest weight loss in the range of 2 to 10 kg, usually most effective during the first 6 months of therapy; however, studies have shown positive effects on other risk factors such as blood pressure and serum glucose levels, but there are fewer studies in patients with diabetes. The aim of this study was to assess the effect of topiramate on weight reduction patients with type 2 diabetes. Materials and Methods: This was a 32‑week randomized clinical trial study of 69 subjects during 2008‑2010. RIGINAL Patients, in two treatment groups were given topiramate (39 patients) and Placebo (30 patients) and were subjected to participation in a non‑pharmacologic lifestyle intervention program; which were randomly allocated in our two groups. The percentage change in body O weight and Body Mass Index (BMI) at the end of the study was the primary efficacy endpoint and secondary indicators were changes in blood pressure (BP), proportion of subjects who achieved 5% or 10% weight loss, changes in lipid profile (total cholesterol, low‑density lipoprotein cholesterol, high‑density lipoprotein cholesterol, triglycerides); and changes in glycosylated hemoglobin (HgA1c). Paired samples and independent samples t‑test was used for statistical analysis.
    [Show full text]
  • Deliberate Self-Poisoning with a Lethal Dose of Pentobarbital: Survival with Supportive Care
    Deliberate self-poisoning with a lethal dose of pentobarbital: Survival with supportive care. (1) (1,2) Santosh Gone , Andis Graudins (1) Clinical Toxicology Service, Program of Emergency Medicine, Monash Health (2) Monash Emergency Research Collaboration, Clinical Sciences at Monash Health, Monash University Abstract 84 INTRODUCTION CASE REPORT (continued) DISCUSSION Pentobarbital (Nembutal) is short acting In the ED: Pentobarbital has been a banned substance for barbiturate sedative-hypnotic, currently widely GCS: 3/15, fixed dilated pupils, apnoeic and human use in Australia since 1998. However, it can used in veterinary practice for anesthesia and ventilated. be procured overseas or bought on the internet. euthanasia. Pulse: 116 bpm sinus tachycardia BP: 115/60 on epinephrine infusion. Pentobarbital is recommended as an effective It is also commonly recommended as a VBG: pH 7.03 pCO2 77 mmHg Bicarb 19 mmol/L agent for use in euthanasia due to its apparently euthanasia drug for assisted suicide and it is Lactate 8.8 mmol/L peaceful transition to death. unlikely that any resuscitative measures will be Activated charcoal (50g) given via an NG tube. attempted in such cases. Course in the Intensive Care Department: In a case series of 150 assisted suicides in Day-1 post-OD: Sweden, a 100% success rate was seen with Intentional overdose results in depression of - Absent brain stem reflexes and fixed dilated pupils for ingestion of 9 grams. Cardiovascular collapse was brain stem function and rapid onset respiratory five days. seen within 15 minutes in 30% of patients. It is rare depression and apnoea. Hypotension also - Diabetes insipidus developed with urine output of to see survival after intentional ingestion for develops, followed by cardiovascular collapse 300ml/hour.
    [Show full text]
  • Pentobarbital Sodium
    PENTobarbital Sodium Brand names Nembutal Sodium Medication error Look-alike, sound-alike drug names. Tall man letters (not FDA approved) are recommended potential to decrease confusion between PENTobarbital and PHENobarbital.(1,2) ISMP recommends the following tall man letters (not FDA approved): PENTobarbital.(30) Contraindications Contraindications: In patients with known hypersensitivity to barbiturates or any com- and warnings ponent of the formulation.(2) If an allergic or hypersensitivity reaction or a life-threatening adverse event occurs, rapid substitution of an alternative agent may be necessary. If pentobarbital is discontinued due to development of a rash, an anticonvulsant that is structurally dissimilar should be used (i.e., nonaromatic). (See Rare Adverse Effects in the Comments section.) Also contraindicated in patients with a history of manifest or latent porphyria.(2) Warnings: Rapid administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with hypotension.(2) Should be withdrawn gradually if large doses have been used for prolonged periods.(2) Paradoxical excitement may occur or important symptoms could be masked when given to patients with acute or chronic pain.(2) May be habit forming. Infusion-related Respiratory depression and arrest requiring mechanical ventilation may occur. Monitor cautions oxygen saturation. If hypotension occurs, the infusion rate should be decreased and/or the patient should be treated with IV fluids and/or vasopressors. Pentobarbital is an alkaline solution (pH = 9–10.5); therefore, extravasation may cause tissue necrosis.(2) (See Appendix E for management.) Gangrene may occur following inadvertent intra-arterial injection.(2) Dosage Medically induced coma (for persistently elevated intracranial pressure (ICP) or refractory status epilepticus): Patient should be intubated and mechanically ventilated.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Choice of Drugs in the Treatment of Rheumatoid Arthritis
    RHEUMATOLOGY IN GENERAL PRACTICE 7 Those with predominant but never exclusive involvement of the terminal finger joint, usually associated with changes in the nail of the same finger; they are serologically negative. There may be a swollen finger with loss of the skin markings-a sort of dactylitis, again serologically negative. (2) Those with a much more severe process which produces loss of movement in the spine and changes in the sacroiliac joints much the same as those in ankylosing spondylitis; unlike ankylosing spondylitis, it produces severe deformity often with ankylosis in peripheral joints. Many of the finger joints become deformed and ankylosed. (3) Those cases indistinguishable from rheumatoid arthritis although the majority are sero-negative. The Stevens Johnson syndrome produces acute effusions, particularly in large joints. It is sometimes associated with the rash of erythema multiforme, always with ulceration in the mouth and genital tract; the mouth ulcers are accompanied by sloughing, unlike those of Beh9et's syndrome which we come to next. BehCet's syndrome, originally described as a combination of orogenital ulceration with relapsing iritis, is now expanded to include skin lesions, other eye lesions, lesions of the central nervous system, thrombophlebitis migrans, and arthropathy (occurring in 64 per cent). The onset is acute, often affecting only a single joint and settling without residual trouble. Choice of drugs in the treatment of rheumatoid arthritis Dr Dudley Hart, M.D., F.R.C.P. (Consultant physician, Westminster Hospital and Medical School) There are many potential drugs for the treatment of rheumatoid disease, but what are we treating in this disorder? Pain in rheumatoid arthritis is but one of the symp- toms.
    [Show full text]
  • Calcium Current Block by (-)-Pentobarbital, Phenobarbital
    The Journal of Neuroscience, August 1993, 13(E): 321 l-3221 Calcium Current Block by (-)-Pentobarbital, Phenobarbital, and CHEB but not (+)-Pentobarbital in Acutely Isolated Hippocampal CA1 Neurons: Comparison with Effects on GABA-activated Cl- Current Jarlath M. H. ffrench-Mullen,’ Jeffery L. Barker,* and Michael A. Rogawski3 ‘Department of Pharmacology, Zeneca Pharmaceuticals Group, Zeneca Inc., Wilmington, Delaware 19897 and *Laboratory of Neurophysiology, and 3Neuronal Excitability Section, Epilepsy Research Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 Block of a voltage-activated Ca*+ channel current by pheno- Ca*+ current, whereas the sedative effects that occur at high- barbital (PHB), 5-(2-cyclohexylideneethyl)-5-ethyl barbituric er concentrations could reflect stronger Ca2+ current block- acid (CHEB), and the optical R(-)- and S(+)-enantiomers of ade. The powerful sedative-hypnotic action of (-)-PB may pentobarbital (PB) was examined in freshly dissociated adult reflect greater maximal enhancement of GABA responses guinea pig hippocampal CA1 neurons; the effects of the in conjunction with strong inhibition of Ca2+ current. The barbiturates on GABA-activated Cl- current were also char- convulsant action of CHEB is unlikely to be related to its acterized in the same preparation. (-)-PB, PHB, and CHEB effects on the Ca*+ current. produced a reversible, concentration-dependent block of the [Key words: calcium channel, GABA receptor, (-)-pen- peak Ca*+ channel current (3 mM Ba2+ as the charge carrier) tobarbital, (+)-pentobarbital, phenobarbital, CHEB [S-(2-cy- evoked by depolarization from -80 to - 10 mV (I&,, values, clohexylideneethyl)-S-ethyl barbituric acid], CA 1 hippocam- 3.5, 72, and 118 PM, respectively).
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]